Long COVID Research Moonshot Act: A Turning Point for Chronic Illness

The Long COVID Research Moonshot Act (S. 4964), introduced in August 2024, proposes a $1 billion annual investment through 2034 to address the long-term effects of COVID-19 and other infection-associated chronic conditions. The legislation aims to accelerate research, improve patient care, and lay the groundwork for a broader understanding of how infections can contribute to chronic disease.

The bill directs the NIH to establish a Long COVID Research Program, a centralized initiative to investigate causes, risk factors, and treatment strategies. The program would support scientific studies, clinical trials, and public health efforts, with a strong emphasis on collaboration across agencies, transparency, and input from patient communities.

Key features of the bill include:

  • Fast-tracked research funding for therapies, diagnostics, and data collection, including for children and underserved populations.
  • Comparative studies examining the overlap between Long COVID and conditions such as ME/CFS, postural orthostatic tachycardia syndrome (POTS), and chronic Lyme disease.
  • Public data sharing through a registry of clinical trials and a centralized research clearinghouse.
  • Pricing protections to ensure federally funded treatments are affordable to the public.
  • Public health infrastructure, including grants to state and local health departments for education, training, and care coordination.
  • Dedicated Long COVID clinics to deliver integrated, multidisciplinary care nationwide.

The bill recognizes that post-viral illness is not unique to COVID-19. Increasing evidence links infection to a wide range of chronic conditions, including autoimmune diseases, neurodegenerative disorders, and cardiovascular issues.

By investing in this field, the United States could not only improve outcomes for millions currently living with Long COVID but also unlock new insights into the infectious roots of chronic disease more broadly.